Saxsons Group — India's trusted nuclear medicine, radiotherapy, oncosurgery, dosimetry and cyclotron supplier since 1986

All research papers

2996 approved papers, newest first · showing 121–180.Search instead →

  1. 8 Oct 2026· The Journal of urology· Ga-68 PSMA PET· Diagnostic
    Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography / Magnetic Resonance Imaging in Selected Men with Equivocal Prostate Imaging Reporting and Data System Category 3 Lesion (PANDORA): A Prospective Paired Diagnostic Study.
    Diamand R et al.
  2. 8 Oct 2026· Endocrine-related cancer· Lu-177 DOTATATE· Therapeutic
    Applying 177Lu-Dotatate for Hereditary Neuroendocrine Tumours: The Role in MEN1.
    Becx MN et al.
  3. 7 Oct 2026· Frontiers in oncology· SBRT delivery· Therapeutic· Free full text
    LASSO-based nomogram to predict early treatment failure in advanced hepatocellular carcinoma treated with SBRT, lenvatinib, and tislelizumab.
    Zhao Y et al.
  4. 7 Oct 2026· Frontiers in oncology· MR-linac / MR-guided· Therapeutic· Free full text
    A prospective pilot study of urine microRNA as a biomarker of urinary radiation toxicity following MRI-guided prostate stereotactic body radiotherapy.
    Smyczyńska U et al.
  5. 7 Oct 2026· Clinical and translational radiation oncology· Adaptive radiotherapy· Therapeutic
    Feasibility and potential benefits of daily online adaptive radiotherapy for head and neck cancer without margin reduction using an RTT-only workflow.
    Lindegaard AM et al.
  6. 7 Oct 2026· Journal of neuro-oncology· SRS / intracranial· Therapeutic
    Volumetric analysis of radiographic changes after stereotactic radiosurgery for treatment of non-responding brain metastases.
    Rajkumar S et al.
  7. 7 Oct 2026· Journal of medical imaging and radiation oncology· SBRT delivery· Therapeutic
    Linear Accelerator-Based Stereotactic Body Radiotherapy of 36.25 Gy in Five Fractions for Localised Prostate Cancer: A Retrospective Single-Institution Cohort Study.
    Katano A et al.
  8. 7 Oct 2026· Journal of clinical oncology· SBRT delivery· Therapeutic
    NRG-BR002: A Randomized Phase II/III Trial of Metastasis-Directed Ablation With First-Line Systemic Therapy for Oligometastatic Breast Cancer.
    Chmura SJ et al.
  9. 7 Oct 2026· ACS applied bio materials· Ra-223· Therapeutic
    'All-in-One' Micro- and Nanoscale MOFs for Combined Chemo-Radionuclide Therapy of Breast Cancer.
    Akhmetova D et al.
  10. 7 Oct 2026· The quarterly journal of nuclear medicine and molecular imaging· Lu-177 FAPI· Diagnostic
    The added value of [68Ga]Ga-FAPI-46 PET/CT imaging in oncology: a real-world clinical setting.
    VAN DEN Bos M et al.
  11. 7 Oct 2026· Abdominal radiology (New York)· Lu-177 FAPI· Diagnostic
    Diagnostic performance of [<sup>18</sup>F]-FDG or [<sup>68</sup>Ga]-FAPI PET/MRI for nodal assessment in colorectal cancer: a retrospective comparative analysis.
    Zhao M et al.
  12. 7 Oct 2026· European radiology· Lu-177 FAPI· Diagnostic
    Preoperative [<sup>18</sup>F]FAPI-42 PET/CT is associated with tumor budding in colorectal cancer: a dual-center retrospective study.
    Mu X et al.
  13. 7 Oct 2026· International journal of molecular sciences· Lu-177 FAPI· Diagnostic
    Tracking Active Fibroblast-Mediated Tissue Remodelling in Cardiomyopathies: Translational Insights from FAPI PET Imaging.
    Fortuna I et al.
  14. 6 Oct 2026· Technical innovations & patient support in radiation oncology· Adaptive radiotherapy· Therapeutic
    An in-house timer for ART-specific extra time in gynecologic pelvic online adaptive radiation therapy.
    Zheng Y et al.
  15. 6 Oct 2026· Practical radiation oncology· In-vivo dosimetry· QA & dosimetry
    Medical Physicist-Patient Consultation Enhances the Reproducibility of Treatment Delivery in Radiation Therapy for Breast Cancer: An EPID-Based In Vivo Transit Dosimetry Study.
    Marino C et al.
  16. 6 Oct 2026· Radiation and environmental biophysics· Patient-specific QA· QA & dosimetry
    Characterization of high-resolution detector response for stereotactic patient-specific QA across different TPS-linac systems.
    Sahin S et al.
  17. 6 Oct 2026· Nuclear medicine communications· Ac-225 alpha therapy· Therapeutic
    Publication trends and knowledge structure of prostate-specific membrane antigen radioligand therapy for prostate cancer: a bibliometric analysis, 2015-2025.
    Long H et al.
  18. 6 Oct 2026· BMJ open· SBRT delivery· Therapeutic
    Metastasis-directed radiotherapy (MDRT) for men with de novo, oligometastatic prostate cancer treated with long-term androgen deprivation therapy in the STAMPEDE trial (METANOVA): protocol for a multicentre, phase II randomised controlled trial in the USA.
    Lichtman-Mikol S et al.
  19. 5 Oct 2026· Neuroradiology· SRS / intracranial· Therapeutic
    Multifocal intracranial epstein-barr virus-associated smooth muscle tumors in an HIV-positive patient: incidental discovery and treatment with staged gamma knife radiosurgery.
    Sutanto R et al.
  20. 5 Oct 2026· Journal of neuro-oncology· SRS / intracranial· Therapeutic
    Dose selection and clinical decision-making after Gamma Knife surgery for large brain metastases: implications for early identification of true progression.
    Koketsu Y et al.
  21. 5 Oct 2026· Clinical spine surgery· SBRT delivery· Therapeutic
    Radiotherapy Advances for Cervical Spine Tumors: Conventional Versus Stereotactic Body Radiotherapy (SBRT).
    Lilly DT et al.
  22. 5 Oct 2026· Journal of medical imaging and radiation oncology· SBRT delivery· Therapeutic
    Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation for the Treatment of Early-Stage Hepatocellular Carcinoma.
    Egan D et al.
  23. 5 Oct 2026· Physics in medicine and biology· SBRT delivery· Therapeutic
    Introduce 4π dynamic spot-scanning proton arc therapy (SPArc-4π) for pancreatic cancer: a comparative planning study with IMPT.
    Chen P et al.
  24. 5 Oct 2026· European urology open science· SBRT delivery· Therapeutic
    Oligoprogressive Renal Cell Carcinoma Treated with Stereotactic Body Radiation Therapy Versus Switching to a New Systemic Therapy.
    Franzese C et al.
  25. 5 Oct 2026· Applied radiation and isotopes· TLD dosimetry· QA & dosimetry
    Validation of a 3D-printed anthropomorphic eye phantom for quality assurance in external beam radiotherapy using TLD and radiochromic film.
    Fidelis ALE et al.
  26. 5 Oct 2026· Nuklearmedizin. Nuclear medicine· I-131 therapy· Therapeutic
    Marinelli Equation vs. DIN 6861-1: Comparison of the Achieved Therapeutic Thyroid Dose after Radioiodine Therapy Using Different Pretherapeutic Dosimetry.
    Heilfort P et al.
  27. 5 Oct 2026· The international journal of cardiovascular imaging· Lu-177 FAPI· Diagnostic
    Molecular phenotyping of atrial remodeling in atrial fibrillation using <sup>18</sup>F-FDG and <sup>18</sup>F-FAPI PET.
    Duan SD et al.
  28. 5 Oct 2026· JCEM case reports· Lu-177 DOTATATE· Therapeutic· Free full text
    A case of metastasectomy following multiple courses of radionuclide therapy for distant metastatic pheochromocytoma.
    Wada N et al.
  29. 4 Oct 2026· Radiotherapy and oncology· Adaptive radiotherapy· Therapeutic
    Early target volume dynamics during MR-guided radiotherapy for glioblastoma: first results from the prospective MARGA-I trial.
    Kretzschmar L et al.
  30. 4 Oct 2026· Advanced healthcare materials· Radiopharmaceutical QC· Diagnostic· Radiopharmacy
    Synthesis, Preclinical Evaluation, and Clinical Application of the FAPI-Dimer Based on the LARM Platform.
    Jia F et al.
  31. 3 Oct 2026· Annals of biomedical engineering· Adaptive radiotherapy· QA & dosimetry
    Evaluating Image Quality of Cone Beam Computed Tomography Using HyperSight® on the Varian TrueBeam.
    Lohela J et al.
  32. 3 Oct 2026· Japanese journal of radiology· SBRT delivery· Therapeutic
    Long-term results of stereotactic body radiotherapy boost in patients with cervical cancer considered unsuitable for intracavitary brachytherapy.
    Ito K et al.
  33. 3 Oct 2026· Annals of nuclear medicine· I-131 therapy· Therapeutic
    Dose-activity relationship in [<sup>131</sup>I]NaI therapy for differentiated thyroid carcinoma.
    Luján-Expósito Á.
  34. 3 Oct 2026· Annals of nuclear medicine· Ga-68 PSMA PET· Diagnostic
    Reconstruction robustness of liver-referenced adaptive thresholding for <sup>68</sup>Ga-PSMA-11 PET/CT volumetry: a comparative analysis of systematic bias and individual-patient variability.
    Schötz E et al.
  35. 3 Oct 2026· Japanese journal of radiology· Ga-68 PSMA PET· Diagnostic
    Diagnostic accuracy of <sup>18</sup>F-PSMA-1007 PET/CT and bone scintigraphy for detecting bone metastases in prostate cancer.
    Kitajima K et al.
  36. 3 Oct 2026· European urology· Ga-68 PSMA PET· Diagnostic
    PSMA-PET/CT-guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): 5-yr Analysis of a Phase 2 Randomized Controlled Trial.
    Belliveau C et al.
  37. 2 Oct 2026· Frontiers in oncology· Adaptive radiotherapy· Therapeutic
    CBCT-based adaptive radiotherapy and automated radiotherapy decision-making systems: development and current status.
    Wang S et al.
  38. 2 Oct 2026· Frontiers in endocrinology· I-131 therapy· Therapeutic
    An explainable and leakage-aware machine learning model for early risk stratification of radioiodine-refractory differentiated thyroid cancer: development and single-center geographic external validation.
    Tan G et al.
  39. 2 Oct 2026· Frontiers in oncology· Ga-68 PSMA PET· Theranostic
    Comparative analysis of treatment response to PSMA radioligand therapy using Ga-68 PSMA-11 and F-18 DCFPyL PET imaging.
    Hong CM et al.
  40. 2 Oct 2026· Biomedical physics & engineering express· Adaptive radiotherapy· Therapeutic
    External evaluation of a deep learning-based algorithm for automated lung tumor and esophagus segmentation on CBCT.
    Zhang Z et al.
  41. 1 Oct 2026· Nuclear medicine and biology· Radiopharmaceutical QC· Radiopharmacy
    Production of no-carrier-added theranostic Au-199: A systematic evaluation of liquid-liquid extraction from dissolved neutron-irradiated platinum targets.
    Pressler M et al.
  42. 1 Oct 2026· Clinical oncology (Royal College of Radiologists (Great Britain))· Breast / lung positioning· Therapeutic
    Respiratory Instability-driven Cardiac Dose Deviation in Postmastectomy Deep Inspiration Breath-hold Volumetric Modulated Arc Therapy (DIBH VMAT): Development and External Validation of a Respiratory-informed Predictive Framework.
    Singh S et al.
  43. 1 Oct 2026· Cancer medicine· I-131 therapy· Therapeutic· Free full text
    Apparent Survival Benefit of Postoperative Radioactive Iodine in Lymph Node-Positive Papillary Thyroid Carcinoma: A Negative-Control Analysis for Unmeasured Confounding.
    Liu T et al.
  44. 1 Oct 2026· Molecular pharmaceutics· Ac-225 alpha therapy· Theranostic
    134Ce/134La Radiotheranostics from PET Surrogation of 225Ac to Auger and Conversion-Electron Therapy.
    Brejeon A et al.
  45. 1 Oct 2026· Molecular pharmaceutics· Ac-225 alpha therapy· Therapeutic
    Preclinical Evaluation of [225Ac]Ac-NM600 Therapeutic Potential for Localized and Metastatic Triple-Negative Breast Cancer.
    Medina Guevara Y et al.
  46. 1 Oct 2026· Journal of medicinal chemistry· Ac-225 alpha therapy· Therapeutic
    Development of Novel 211At-Labeled Agent for Neurotensin Receptor 1-Targeted α-Particle Therapy.
    Otsu M et al.
  47. 1 Oct 2026· Molecular pharmaceutics· Lu-177 FAPI· Therapeutic
    Novel Covalent FAP-Targeted Radiotherapy Drug Based on DOTA-FAP-2286 for Enhanced Tumor Uptake, Retention, and Therapeutic Efficacy.
    Tang S et al.
  48. 1 Oct 2026· Journal of medicinal chemistry· Lu-177 FAPI· Diagnostic· Radiopharmacy
    Spirocyclic Reconfiguration of the Piperazine Linker Improves Quinoline-Based FAPI PET Tracer Performance.
    Wu W et al.
  49. 1 Oct 2026· Journal of medicinal chemistry· Lu-177 FAPI· Diagnostic· Radiopharmacy
    [18F]FPyQCP: A Robust FAP-Targeted PET Tracer Integrating Covalent C-18F Labeling and Radiometal Chelation for Enhanced In Vivo Performance.
    Banerjee SR et al.
  50. 1 Oct 2026· Journal of neuroendocrinology· Ga-68 DOTATATE· Theranostic
    Neuropeptides and their receptors in CNS cancer imaging/theranostics: Review of recent advances and increased interest with emphasis on the somatostatin/bombesin/substance P peptide receptor families.
    Moody TW et al.
  51. 1 Oct 2026· Journal of applied clinical medical physics· Radiation safety· Free full text
    Development and validation of a pregnant phantom with adjustable fetal presentation for region-specific fetal radiation dose assessment during pelvic radiography.
    Matsunaga Y et al.
  52. 1 Oct 2026· Journal of radiation research· Gold-anchor fiducial markers· Therapeutic· Free full text
    Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial.
    Iizumi T et al.
  53. 1 Oct 2026· Journal of biomedical physics & engineering· TLD dosimetry· QA & dosimetry
    Comparison of the Measurement Uncertainty of Thermoluminescence Dosimeters (TLD-100 and GR-200) in Clinical Radiotherapy Energies.
    Sadeghi B et al.
  54. 1 Oct 2026· Journal of applied clinical medical physics· Adaptive radiotherapy· QA & dosimetry
    Retrospective log-based quality assurance of real-time MLC adaptation on a helical tomotherapy platform.
    Crowe SB et al.
  55. 1 Oct 2026· Journal of applied clinical medical physics· Adaptive radiotherapy· Therapeutic
    Frequency Schrödinger bridge diffusion model for fast MRI reconstruction in abdominal MR-guided online adaptive radiotherapy.
    Wang Z et al.
  56. 1 Oct 2026· Medical physics· MR-linac / MR-guided· Diagnostic
    Simultaneous T1, T2, R2*, PDFF, and triglyceride quantification in the head and neck using magnetic resonance fingerprinting on a 1.5T MR-Linac.
    McCullum L et al.
  57. 1 Oct 2026· Journal of applied clinical medical physics· SRS / intracranial· Therapeutic
    Longitudinal trends in Gamma Knife radiosurgery utilization across multiple technological generations: A Single-Institution Observational Study.
    El Basha D et al.
  58. 1 Oct 2026· BMJ open· SBRT delivery· Therapeutic· Free full text
    Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol.
    Li J et al.
  59. 1 Oct 2026· Journal of applied clinical medical physics· Adaptive radiotherapy· Therapeutic· Free full text
    Evaluation of online dose-guided adaptive fractionation for intact prostate radiotherapy.
    Gevorkyan GS et al.
  60. 1 Oct 2026· Clinical and translational radiation oncology· SBRT delivery· Therapeutic· Free full text
    Efficacy and safety of single-fraction stereotactic body radiotherapy (SBRT) for the curative treatment of extracranial primary Tumors: A collaborative systematic review on behalf of the SBRT Focus Group of the European Society for Radiotherapy & Oncology (ESTRO).
    Cuccia F et al.